Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Advaxis, City of Hope collaborate on leukemia, lymphoma vaccines
September 2009
SHARING OPTIONS:

NORTH BRUNSWICK, N.J.Advaxis Inc., a developer of live, attenuated Listeria monocytogenes (Lm) vaccines, announced in August that it will collaborate with investigators at City of Hope on the development of a vaccine for the treatment of certain forms of leukemia and lymphoma. City of Hope investigators are studying a vaccine provided by Advaxis directed against the tumor-associated antigen WT-1. This molecule is observed to be over-expressed in certain cancers of the blood as well as some solid tumors such as breast, pancreas and brain cancers, which makes it a potential target for a selective immune attack delivered via an Lm vector designed by Advaxis. Financial details were not released.          

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.